AI-generated summary
This review examines the available data on photobiomodulation therapy for age-related macular degeneration. The authors report that the therapy might be used for nonexudative disease and that limited evidence suggests possible benefit in exudative disease. They note that more studies are needed to evaluate its efficacy and that safe upper dose limits have not been established.
- Who or what was studied
- Patients with age-related macular degeneration (nonexudative and exudative forms)
- Limits stated in the abstract
- The abstract states that evidence is limited and that more studies are needed to evaluate efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 60 J/cm2
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation therapy, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.